Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.73 |
| ▸ | F10 | P00742 | 1/20 | 0.73 |
| ▸ | F12 | P00748 | 1/20 | 0.73 |
| ▸ | F7 | P08709 | 1/20 | 0.73 |
| ▸ | F3 | P13726 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.67 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.67 |
| ▸ | C1S | P09871 | 2/20 | 0.67 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | WDR5 | P61964 | 1/20 | 0.61 |
| ▸ | NQO2 | P16083 | 3/20 | 0.53 |
| ▸ | PLAU | P00749 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MASP2 | O00187 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204318 | 0.91 | LMNA (0.59) | F2F10F12F7F3 | |
| Hydrochloric Acid SCHEMBL982825 | 0.88 | PRSS1 (0.61) | F2F10F12F7F3 | |
| Bromide SCHEMBL5619195 | 0.88 | LMNA (0.56) | F2F10F12F7F3 | |
| Hydrochloric Acid SCHEMBL9338860 | 0.86 | LMNA (0.54) | F2F10F12F7F3 | |
| Benzamidine SCHEMBL23067876 | 0.85 | F2 (1.00) | F2F10F12F7F3 | |
| SCHEMBL18557033 | 0.85 | F2 (1.00) | F2F10F12F7F3 | |
| Benzamidine SCHEMBL27781057 | 0.85 | F2 (1.00) | F2F10F12F7F3 | |
| Benzamidine SCHEMBL9207 | 0.85 | — | — | |
| SCHEMBL27438192 | 0.84 | WDR5 (0.64) | F2F10F12F7F3 | |
| Benzamidine SCHEMBL2877747 | 0.83 | F2 (0.94) | F2F10F12F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| CN-101687869-A | Tetracyclic lactam derivatives as MK2 inhibitors | NOVARTIS AG | 2010-03-31 | — | — | CN | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | F2 633/4885F10 1702/4885F12 396/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | F2 633/4885F10 1702/4885F12 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.